Cellebrite DI Ltd. $CLBT Shares Sold by Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD

Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD reduced its position in Cellebrite DI Ltd. (NASDAQ:CLBT) by 1.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 373,768 shares of the company’s stock after selling 6,313 shares during the period. Cellebrite DI comprises about 1.3% of Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD’s portfolio, making the stock its 26th biggest holding. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD’s holdings in Cellebrite DI were worth $5,984,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Assetmark Inc. acquired a new position in shares of Cellebrite DI in the 1st quarter valued at $33,000. Signaturefd LLC lifted its stake in shares of Cellebrite DI by 68.3% in the 2nd quarter. Signaturefd LLC now owns 2,019 shares of the company’s stock valued at $32,000 after purchasing an additional 819 shares during the period. Catalyst Capital Advisors LLC acquired a new position in Cellebrite DI during the first quarter worth $51,000. Virtus Advisers LLC acquired a new position in Cellebrite DI during the first quarter worth $63,000. Finally, Hennessy Advisors Inc. acquired a new position in Cellebrite DI during the second quarter worth $83,000. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Cellebrite DI from a “hold” rating to a “buy” rating in a research report on Friday, September 26th. JPMorgan Chase & Co. upped their price objective on shares of Cellebrite DI from $20.00 to $23.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 24th. Weiss Ratings restated a “sell (d+)” rating on shares of Cellebrite DI in a research report on Wednesday, October 8th. Lake Street Capital reduced their price objective on shares of Cellebrite DI from $24.00 to $22.00 and set a “buy” rating for the company in a research report on Friday, August 15th. Finally, Needham & Company LLC reduced their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, August 14th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $21.75.

Cellebrite DI Price Performance

Shares of CLBT stock opened at $18.42 on Friday. The firm has a market cap of $4.41 billion, a PE ratio of -24.24, a price-to-earnings-growth ratio of 3.23 and a beta of 1.29. The company has a 50-day moving average of $17.56 and a two-hundred day moving average of $16.93. Cellebrite DI Ltd. has a 1-year low of $13.10 and a 1-year high of $26.30.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.01. The company had revenue of $113.28 million during the quarter, compared to analyst estimates of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. Cellebrite DI’s revenue was up 18.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.10 earnings per share. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Sell-side analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.